HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease.

Abstract
Alzheimer's disease, the most common cause of dementia in the elderly and characterized by the deposition and accumulation of plaques, is composed in part of β-amyloid (Aβ) peptides, loss of neurons, and the accumulation of neurofibrillary tangles. Here, we describe ponezumab, a humanized monoclonal antibody, and show how it binds specifically to the carboxyl (C)-terminus of Aβ40. Ponezumab can label Aβ that is deposited in brain parenchyma found in sections from Alzheimer's disease casualties and in transgenic mouse models that overexpress Aβ. Importantly, ponezumab does not label full-length, non-cleaved amyloid precursor protein on the cell surface. The C-terminal epitope of the soluble Aβ present in the circulation appears to be available for ponezumab binding because systemic administration of ponezumab greatly elevates plasma Aβ40 levels in a dose-dependent fashion after administration to a mouse model that overexpress human Aβ. Administration of ponezumab to transgenic mice also led to a dose-dependent reduction in hippocampal amyloid load. To further explore the nature of ponezumab binding to Aβ40, we determined the X-ray crystal structure of ponezumab in complex with Aβ40 and found that the Aβ40 carboxyl moiety makes extensive contacts with ponezumab. Furthermore, the structure-function analysis supported this critical requirement for carboxy group of AβV40 in the Aβ-ponezumab interaction. These findings provide novel structural insights into the in vivo conformation of the C-terminus of Aβ40 and the brain Aβ-lowering efficacy that we observed following administration of ponezumab in transgenic mouse models.
AuthorsSherry L La Porte, Sangeetha Subbarao Bollini, Thomas A Lanz, Yasmina N Abdiche, Alexander S Rusnak, Wei-Hsien Ho, Dione Kobayashi, Ons Harrabi, Danielle Pappas, Erene W Mina, Anthony J Milici, Thomas T Kawabe, Kelly Bales, John C Lin, Jaume Pons
JournalJournal of molecular biology (J Mol Biol) Vol. 421 Issue 4-5 Pg. 525-36 (Aug 24 2012) ISSN: 1089-8638 [Electronic] Netherlands
PMID22197375 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Elsevier Ltd. All rights reserved.
Chemical References
  • Amyloid beta-Peptides
  • Antibodies, Monoclonal, Humanized
  • Neuroprotective Agents
  • ponezumab
Topics
  • Alzheimer Disease (drug therapy, pathology, physiopathology)
  • Amino Acid Sequence
  • Amyloid beta-Peptides (blood, chemistry, metabolism)
  • Animals
  • Antibodies, Monoclonal, Humanized (administration & dosage, chemistry, metabolism)
  • Brain (pathology)
  • Crystallography, X-Ray
  • Disease Models, Animal
  • Humans
  • Injections, Intravenous
  • Mice
  • Mice, Transgenic
  • Models, Molecular
  • Molecular Sequence Data
  • Neuroprotective Agents (administration & dosage, chemistry, metabolism)
  • Plasma (chemistry)
  • Protein Binding
  • Protein Conformation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: